Sidoti Csr Has Bullish Forecast for Kamada FY2025 Earnings

Key Points

• Sidoti Csr has revised its FY2025 earnings per share (EPS) estimate for Kamada Ltd. to $0.33, an increase from the previous estimate of $0.28.
• Weiss Ratings has maintained a buy rating for Kamada, with three analysts giving it a Buy rating and one issuing a Hold rating, reflecting confidence in the stock's potential.
• Kamada's recent earnings report revealed a quarterly EPS of $0.13, surpassing analyst expectations, but revenue was significantly below consensus targets at $44.75 million compared to an expected $158.59 million.

Kamada Ltd. (NASDAQ:KMDA - Free Report) - Investment analysts at Sidoti Csr boosted their FY2025 EPS estimates for shares of Kamada in a research note issued on Thursday, October 2nd. Sidoti Csr analyst J. Sidoti now expects that the biotechnology company will earn $0.33 per share for the year, up from their previous forecast of $0.28. The consensus estimate for Kamada's current full-year earnings is $0.23 per share. Sidoti Csr also issued estimates for Kamada's Q1 2027 earnings at $0.08 EPS, Q2 2027 earnings at $0.11 EPS, Q3 2027 earnings at $0.12 EPS and FY2027 earnings at $0.42 EPS.

Kamada (NASDAQ:KMDA - Get Free Report) last posted its earnings results on Wednesday, August 13th. The biotechnology company reported $0.13 EPS for the quarter, beating analysts' consensus estimates of $0.09 by $0.04. Kamada had a return on equity of 7.41% and a net margin of 11.22%.The company had revenue of $44.75 million for the quarter, compared to the consensus estimate of $158.59 million. Kamada has set its FY 2025 guidance at EPS.

Separately, Weiss Ratings reiterated a "buy (b-)" rating on shares of Kamada in a research report on Saturday, September 27th. Three analysts have rated the stock with a Buy rating and one has issued a Hold rating to the company. Based on data from MarketBeat.com, the company presently has an average rating of "Moderate Buy" and a consensus price target of $13.00.

Kamada Trading Up 0.3%

Shares of KMDA opened at $6.82 on Monday. The company's 50-day moving average price is $7.08 and its 200 day moving average price is $7.00. Kamada has a 12-month low of $5.17 and a 12-month high of $9.15. The firm has a market cap of $392.22 million, a P/E ratio of 20.06, a price-to-earnings-growth ratio of 0.69 and a beta of 0.84.

Institutional Trading of Kamada

Hedge funds and other institutional investors have recently bought and sold shares of the business. Trexquant Investment LP acquired a new position in shares of Kamada during the 1st quarter worth about $82,000. Cubist Systematic Strategies LLC purchased a new stake in Kamada during the first quarter worth approximately $206,000. Jump Financial LLC acquired a new position in Kamada in the second quarter valued at approximately $219,000. NewEdge Advisors LLC increased its stake in Kamada by 119.9% in the first quarter. NewEdge Advisors LLC now owns 51,661 shares of the biotechnology company's stock valued at $341,000 after purchasing an additional 28,165 shares during the last quarter. Finally, Arrowstreet Capital Limited Partnership acquired a new stake in Kamada during the second quarter worth approximately $472,000. 20.38% of the stock is currently owned by institutional investors and hedge funds.

About Kamada

Kamada Ltd. manufactures and sells plasma-derived protein therapeutics. Its commercial products include KAMRAB/KEDRAB for treating prophylaxis of rabies; CYTOGAM for Prophylaxis of Cytomegalovirus disease in kidney, lung, liver, pancreas, heart, and heart/lung transplants; VARIZIG for post exposure prophylaxis of varicella; WINRHO SDF for immune thrombocytopenic purpura and suppression of rhesus isoimmunization; HEPAGAM B for prevention of hepatitis B recurrence liver transplants and post-exposure prophylaxis; GLASSIA for intravenous AATD; KAMRHO (D) IM for prophylaxis of hemolytic disease of newborns; KAMRHO (D) IV for immune thermobocytopunic purpura; and Echis coloratus and Vipera palaestinae Antiserum for the treatment of snake bite.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.